ML-007C-MA
Sponsors
MapLight Therapeutics
Conditions
Psychosis Associated With Alzheimer's DiseaseSchizophrenia
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
RecruitingNCT06887192
Start: 2025-08-15End: 2027-12-01Target: 300Updated: 2026-08-27
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
RecruitingNCT07459647
Start: 2026-03-31End: 2030-02-01Target: 500Updated: 2026-09-01
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Enrolling by invitationNCT07459660
Start: 2026-03-25End: 2029-03-01Target: 210Updated: 2026-08-07